Biocartis, Nichirei Bioscience Ink Commercialization Agreement for Japan

Jan 07, 2019

NEW YORK (GenomeWeb) – Biocartis announced today it has signed a commercialization agreement with Nichirei Bioscience, a supplier of biological and diagnostics products in Japan.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis, Nichirei Bioscience Ink Commercialization Agreement for Japan

To read the full story....

Breaking News

Palmetto Expands Coverage for Decipher Biosciences Prostate Cancer Test

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

What's Popular?

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

United Airlines Launches COVID-19 Testing Program for Travelers to Hawaii

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

NIH Awardee MatMaCorp Developing SARS-CoV-2 Molecular Test for Rural Hospitals

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

Sponsorships